Trial Profile
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac to a Three-dose Regimen of Engerix-B in Adults (PROTECT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant - VBI Vaccines (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics; Registrational
- Acronyms PROTECT
- Sponsors VBI Vaccines
- 25 Jun 2023 According to a VBI vaccines media release, results form this trial were presented at the European Association for the Study of the Liver (EASL) Congress 2023.
- 25 Jun 2023 Results presented in the Brii Biosciences Media Release.
- 07 Jun 2023 According to a VBI vaccines media release, 3.5 year follow up results from this trial has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL).